Abstract 4631: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors
Matthew R. Tonini(Tango Therapeutics (United States)), Kimberly J. Briggs(Io Therapeutics (United States)), Kevin M. Cottrell(Io Therapeutics (United States)), Jennifer Morawiak(Io Therapeutics (United States)), Adam Crystal(C4 Therapeutics (United States)), Heather DiBenedetto(Io Therapeutics (United States)), Douglas A. Whittington(Amgen (United States)), Yi Yu(Novartis (United States)), Satoshi Yoda(Harvard University), André A. Mignault(Io Therapeutics (United States)), Ellen Hooper(Io Therapeutics (United States)), Binzhang Shen(Tango Therapeutics (United States)), Samuel R. Meier, Hannah Stowe(Massachusetts General Hospital), Minjie Zhang(Xian Yang Central Hospital), Teng Teng(Wuhan University), Heidi Rego(Io Therapeutics (United States)), Shangtao Liu(Tango Therapeutics (United States)), Steven A. Lombardo(Io Therapeutics (United States))
Cited by 1